Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use

Patent metadata

Field	Value
Publication number	US-9561232-B2
Application number	US-201514624376-A
Country	US
Kind code	B2
Filing date	Feb 17, 2015
Priority date	Feb 18, 2014
Publication date	Feb 7, 2017
Grant date	Feb 7, 2017

Abstract

This invention provides methods and compositions for treating nicotine addiction or treating or preventing nicotine cravings in a subject. The method comprises administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt thereof.

First claim

What is claimed is:

1. A method for treating nicotine addiction in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of noribogaine, an ester thereof, or a pharmaceutically acceptable salt of each thereof, wherein said therapeutically effective amount is from about 50 ng to less than 10 μg per kg body weight per day, wherein administration of noribogaine, the ester thereof, or the pharmaceutically acceptable salt of each thereof results in a maximum QT interval prolongation of less than about 60 milliseconds (ms) during treatment.

2. The method of claim 1 , wherein the therapeutically effective amount is from about 50 ng to about 1 μg per kg body weight per day.

3. The method of claim 1 , wherein the noribogaine, the ester thereof, or the pharmaceutically acceptable salt of each thereof is administered by sublingual, intranasal, or intrapulmonary delivery.

4. The method of claim 1 , wherein the therapeutically effective amount is administered once a day.

5. The method of claim 1 , wherein the therapeutically effective amount is administered two or more times per day.

6. A pharmaceutical composition comprising a therapeutically effective amount of noribogaine, an ester thereof, or pharmaceutically acceptable salt of each thereof and a pharmaceutically acceptable excipient, wherein the therapeutically effective amount is an amount that delivers an aggregate amount of noribogaine, ester thereof, or pharmaceutically acceptable salt of each thereof of about 50 ng to about 5 μg per kg body weight per day.

7. The pharmaceutical composition of claim 6 , wherein the therapeutically effective amount of noribogaine, the ester thereof, or the pharmaceutically acceptable salt thereof is an amount that delivers an aggregate amount of noribogaine of about 50 ng to about 1 μg per kg body weight per day.

8. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is formulated for sublingual, intranasal, or intrapulmonary delivery.

9. A method for preventing a nicotine craving in a patient in need thereof, comprising administering to the patient a prophylactically effective amount of noribogaine, an ester thereof, or a pharmaceutically acceptable salt of each thereof, wherein said prophylactically effective amount is from about 50 ng to less than 10 μg per kg body weight per day, wherein administration of noribogaine, the ester thereof, or the pharmaceutically acceptable salt of each thereof results in a maximum QT interval prolongation of less than about 60 ms during treatment.

10. The method of claim 9 , wherein the patient is no longer physically addicted to nicotine.

11. The method of claim 9 , wherein the prophylactically effective amount is from about 50 ng to about 1 μg per kg body weight per day.

12. The method of claim 9 , wherein the noribogaine, the ester thereof, or the pharmaceutically acceptable salt of each thereof is administered by sublingual, intranasal, or intrapulmonary delivery.

13. The method of claim 9 , wherein the noribogaine, the ester thereof, or the pharmaceutically acceptable salt of each thereof is administered on an as-needed basis as determined by the subject.

14. The method of claim 9 , wherein the noribogaine, the ester thereof, or the pharmaceutically acceptable salt thereof is administered before the nicotine craving occurs.

15. The method of claim 9 , wherein the noribogaine, the ester thereof, or the pharmaceutically acceptable salt thereof is administered after the nicotine craving occurs.

16. The method of claim 1 , wherein noribogaine or a pharmaceutically acceptable salt thereof is administered.

17. The pharmaceutical composition of claim 6 , comprising noribogaine or a pharmaceutically acceptable salt thereof.

18. The method of claim 1 , wherein the administration of the noribogaine, the ester thereof, or the pharmaceutically acceptable salt of each thereof results in a QT interval of less than about 450 ms during treatment.

19. A method for treating nicotine addiction in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of noribogaine, an ester thereof, or a pharmaceutically acceptable salt of each thereof, wherein said therapeutically effective amount is from about 50 ng to about 5 μg per kg body weight per day.

20. The method of claim 19 , wherein said therapeutically effective amount is from about 50 ng to about 1 μg per kg body weight per day.

21. A method for preventing a nicotine craving in a patient in need thereof, comprising administering to the patient a prophylactically effective amount of noribogaine, an ester thereof, or a pharmaceutically acceptable salt of each thereof, wherein said prophylactically effective amount is from about 50 ng to about 5 μg per kg body weight per day.

22. The method of claim 21 , wherein said prophylactically effective amount is from about 50 ng to about 1 μg per kg body weight per day.

Assignees

• Demerx Inc

Inventors

• Maillet Emeline
• Friedhoff Lawrence

Classifications

• A61K9/006

  Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays · CPC title

• A61K31/55 Primary

  having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title

• A61K9/007

  Pulmonary tract; Aromatherapy · CPC title